WallStSmart

Evolent Health Inc (EVH)vsTempus AI, Inc. Class A Common Stock (TEM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Evolent Health Inc generates 46% more annual revenue ($2.10B vs $1.43B). TEM leads profitability with a -17.8% profit margin vs -24.1%. EVH earns a higher WallStSmart Score of 52/100 (C-).

EVH

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 2.0Value: 4.7Quality: 3.5
Piotroski: 4/9Altman Z: -0.57

TEM

Avoid

28

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -0.65

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVH2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
46.9%10/10

Revenue surging 46.9% year-over-year

TEM1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
21.6%8/10

Revenue surging 21.6% year-over-year

Areas to Watch

EVH4 concerns · Avg: 3.3/10
PEG RatioValuation
1.934/10

Expensive relative to growth rate

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$508.77M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-131.8%2/10

ROE of -131.8% — below average capital efficiency

TEM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
23.9x2/10

Trading at 23.9x book value

Return on EquityProfitability
-57.2%2/10

ROE of -57.2% — below average capital efficiency

Free Cash FlowQuality
$-18.62M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : EVH

The strongest argument for EVH centers on Price/Book, Revenue Growth. Revenue growth of 46.9% demonstrates continued momentum.

Bull Case : TEM

The strongest argument for TEM centers on Revenue Growth. Revenue growth of 21.6% demonstrates continued momentum.

Bear Case : EVH

The primary concerns for EVH are PEG Ratio, EPS Growth, Market Cap. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : TEM

The primary concerns for TEM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 3.25 is elevated, increasing financial risk.

Key Dynamics to Monitor

EVH profiles as a hypergrowth stock while TEM is a growth play — different risk/reward profiles.

TEM carries more volatility with a beta of 3.72 — expect wider price swings.

EVH is growing revenue faster at 46.9% — sustainability is the question.

TEM generates stronger free cash flow (-19M), providing more financial flexibility.

Bottom Line

EVH scores higher overall (52/100 vs 28/100) and 46.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evolent Health Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company is headquartered in Arlington, Virginia.

Visit Website →

Tempus AI, Inc. Class A Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.

Visit Website →

Want to dig deeper into these stocks?